Alogabat clinical trials
Also written RO7017773.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses alogabat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses alogabat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.CompletedPhase 2Hoffmann-La RocheNCT05630066Written as Alogabat
- A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)CompletedPhase 2Hoffmann-La RocheNCT04299464Written as RO7017773
- A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03847987Written as RO7017773 Phase I Capsule
- A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03774576Written as RO7017773
- Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513CompletedPhase 1Hoffmann-La RocheNCT03507569Written as RO7017773
Codes
What other systems call alogabat · ClinicalTrials.gg INT014200
- UNII (FDA) 0HPA4GK3UHALOGABATConfirmed FDA, Wikidata
- Wikidata Q113239638alogabatConfirmed FDA, Wikidata
- NCI Thesaurus C184899AlogabatOne source FDA
- DrugBank DB18708One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0HPA4GK3UH | ALOGABAT | Confirmed FDA, Wikidata |
| Wikidata | Q113239638 | alogabat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C184899 | Alogabat | One source FDA |
| DrugBank | DB18708 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.